Sterilization Method Using Plasma
    1.
    发明公开

    公开(公告)号:US20240252701A1

    公开(公告)日:2024-08-01

    申请号:US18632473

    申请日:2024-04-11

    IPC分类号: A61L2/14 A61L101/02

    摘要: Sterilization method using plasma for sterilizing objects, wherein it is provided to introduce the objects to be sterilized into a sterilization chamber (13) and covey toward the latter a flow of air coming from a feed pipe (17) on which a plasma generator device (30) is disposed able to generate one or more gaseous compounds comprising a mixture of reactive oxygen species (ROS) and of reactive nitrogen species (RNS) so that the air is the carrier fluid which conveys the gaseous compounds toward the sterilization chamber (13); the method also provides to control the electric power used to produce the plasma as a function of the composition and/or the quantity of reactive species present in the sterilization chamber (13).

    Sterilization Method Using Plasma

    公开(公告)号:US20210236674A1

    公开(公告)日:2021-08-05

    申请号:US16972025

    申请日:2019-06-07

    IPC分类号: A61L2/14

    摘要: Sterilization method using plasma for sterilizing objects, wherein it is provided to introduce the objects to be sterilized into a sterilization chamber (13) and covey toward the latter a flow of air coming from a feed pipe (17) on which a plasma generator device (12) is disposed able to generate one or more gaseous compounds comprising a mixture of reactive oxygen species (ROS) and of reactive nitrogen species (RNS) so that the air is the carrier fluid which conveys the gaseous compounds toward the sterilization chamber (13); the method also provides to control the electric power used to produce the plasma as a function of the composition and/or the quantity of reactive species present in the sterilization chamber (13).

    Herpesvirus with modified glycoprotein B

    公开(公告)号:US11007236B2

    公开(公告)日:2021-05-18

    申请号:US16307683

    申请日:2017-06-08

    摘要: The present invention is directed to a recombinant herpesvirus comprising a heterologous polypeptide ligand capable of binding to a target molecule and fused to or inserted into glycoprotein B at specific sites. The herpesvirus may comprise more than one ligand, and the additional ligand(s) may be comprised by a modified glycoprotein D and/or modified glycoprotein H. This allows the herpesvirus to target a cell for therapeutic purposes, and a cell for virus production. The present invention further comprises a pharmaceutical composition comprising the herpesvirus, the herpesvirus for use in the treatment of a tumor, infection, degenerative disorder or senescence-associated disease, a nucleic acid and a vector coding for the gB, a polypeptide comprising the gB, and a cell comprising the herpesvirus, nucleic acid, vector or polypeptide. Moreover, a method for infecting a cell with the herpesvirus or for producing the herpesvirus is disclosed.